Spain’s competition authority, the CNMC, has announced that it is investigating Sandoz and its Bexal subsidiary – as well as other companies Alliance Healthcare España and Bluetab Solutions – over the exchange of sensitive commercial information relating to orders placed by pharmacies for Sandoz/Bexal generics.
The CNMC said that the alleged exchange of “sensitive, unjustified and disaggregated commercial information” took place from April 2018 to April 2023